PMV Pharmaceuticals, Inc (PMVP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PMVP SEC filings page.
This page shows PMV Pharmaceuticals, Inc (PMVP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
PMV remains a development-stage business: rising research investment is consuming cash while its liquid balance sheet steadily shrinks.
From FY2024 to FY2025, research and development spending rose from$58.5M to$69.9M while operating cash flow worsened from-$51.3M to-$73.6M ; development effort is therefore expanding without yet producing operating cash. The shift is not debt-led: total assets fell from$191.3M to$116.6M while debt-to-equity remained near 0.1x, indicating that the balance-sheet contraction is mainly a consequence of ongoing losses and cash use.
The latest net loss of
Short-term liquidity remains high but is thinning: the current ratio declined from 14.8x in FY2023 to 10.1x in FY2025, while reported cash, equivalents, and investments equaled
Financial Health Signals
PMV Pharmaceuticals, Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
PMV Pharmaceuticals, Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
PMV Pharmaceuticals, Inc reported a net loss of $77.7M while operations used $73.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
PMV Pharmaceuticals, Inc reported an operating loss of $86.2M against $6.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
PMV Pharmaceuticals, Inc's EBITDA was -$18.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 17.5% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.
PMV Pharmaceuticals, Inc reported -$18.1M in net income in Q2 2026. This represents an increase of 14.7% from the same quarter a year earlier. Against the prior quarter it is down 0.3%.
PMV Pharmaceuticals, Inc earned -$0.34 per diluted share (EPS) in Q2 2026. This represents an increase of 17.1% from the same quarter a year earlier. It is unchanged from the prior quarter.
Not reported for Q2 2026.
Cash & Balance Sheet
PMV Pharmaceuticals, Inc recorded an outflow of $14.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 20.4% from the same quarter a year earlier. Against the prior quarter it is up 25.9%.
PMV Pharmaceuticals, Inc held $12.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
PMV Pharmaceuticals, Inc's ROE was -25.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 10.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.8 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
PMV Pharmaceuticals, Inc invested $14.7M in research and development in Q2 2026. This represents a decrease of 20.2% from the same quarter a year earlier. Against the prior quarter it is down 4.3%.
PMV Pharmaceuticals, Inc reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2026.
PMVP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $14.7M-20.2% | $15.3M-12.1% | N/A | $18.2M+7.5% | $18.4M+25.8% | $17.4M+32.3% | N/A | $16.9M+24.7% |
| SG&A Expenses | $4.2M-6.1% | $3.7M-10.5% | N/A | $4.3M-12.7% | $4.5M-19.2% | $4.1M-18.1% | N/A | $4.9M-18.2% |
| Operating Income | -$18.9M+17.5% | -$19.0M+11.8% | N/A | -$22.5M-2.9% | -$22.9M-13.4% | -$21.6M-18.3% | N/A | -$21.9M-11.5% |
| EBITDA | -$18.9M+17.5% | -$19.0M+11.8% | N/A | -$22.5M-4.5% | -$22.8M-15.4% | -$21.5M-20.5% | N/A | -$21.5M-11.7% |
| Interest Expense | $788K-53.4% | $980K-49.4% | N/A | $1.5M-43.4% | $1.7M-39.7% | $1.9M-34.5% | N/A | $2.6M-12.4% |
| Income Tax | $3K-40.0% | N/A | N/A | -$6K-108.1% | $5K+100.0% | -$2.2M | N/A | $74K |
| Net Income | -$18.1M+14.7% | -$18.0M-3.5% | N/A | -$21.1M-9.5% | -$21.2M-1648.6% | -$17.4M-14.2% | N/A | -$19.2M-15.5% |
| EPS (Basic) | -$0.34+17.1% | -$0.340.0% | -$0.34+24.4% | -$0.40-8.1% | -$0.41-1950.0% | -$0.34-13.3% | -$0.45-45.2% | -$0.37-8.8% |
| EPS (Diluted) | -$0.34+17.1% | -$0.340.0% | -$0.34+24.4% | -$0.40-8.1% | -$0.41-1950.0% | -$0.34-13.3% | -$0.45-45.2% | -$0.37-8.8% |
| Diluted Shares (Avg) | 53M+2.6% | 53M+2.7% | N/A | 53M+2.8% | 52M+1.0% | 52M+1.0% | N/A | 52M+5.2% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
PMVP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $82.1M-46.3% | $96.6M-43.4% | $116.6M-39.1% | $133.8M-40.1% | $152.9M-35.7% | $170.6M-28.0% | $191.3M-24.1% | $223.5M-14.4% |
| Current Assets | $81.4M-44.0% | $95.8M-41.4% | $115.2M-34.4% | $132.4M-30.2% | $145.3M-33.6% | $163.5M-19.2% | $175.7M-15.3% | $189.6M-7.6% |
| Cash & Equivalents | $12.5M-71.7% | $39.1M-23.8% | $38.0M-7.1% | $36.3M-25.6% | $44.1M-9.1% | $51.3M+7.7% | $40.9M+8.4% | $48.8M-6.2% |
| Short-Term Investments | $67.0M-31.8% | $54.4M-50.1% | $75.0M-41.7% | $92.9M-30.7% | $98.1M-40.3% | $109.0M-27.4% | $128.6M-22.2% | $134.0M-10.6% |
| Long-Term Investments | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $6.0M | $5.4M-64.1% | $13.8M-45.7% | $15.1M-58.3% |
| Total Liabilities | $10.6M-13.7% | $8.6M-18.2% | $11.8M-22.1% | $12.8M-49.8% | $12.3M-47.3% | $10.5M-56.6% | $15.2M-42.5% | $25.6M+9.3% |
| Current Liabilities | $10.6M-9.0% | $8.6M-11.9% | $11.4M-20.6% | $12.3M-9.3% | $11.6M+1.9% | $9.8M-19.1% | $14.4M+2.4% | $13.6M+26.6% |
| Non-Current Liabilities | $0-100.0% | $0-100.0% | $435K-48.1% | $541K-95.5% | $643K-94.6% | $742K-93.9% | $838K-93.3% | $12.0M-5.3% |
| Total Equity | $71.5M-49.1% | $88.0M-45.1% | $104.7M-40.5% | $121.0M-38.9% | $140.6M-34.4% | $160.1M-24.7% | $176.1M-22.0% | $197.9M-16.7% |
| Retained Earnings | -$482.6M-18.5% | -$464.5M-20.3% | -$446.5M-21.1% | -$428.4M-23.9% | -$407.4M-24.8% | -$386.1M-18.7% | -$368.7M-18.9% | -$345.7M-17.5% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
PMVP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.6M+20.4% | -$19.7M-7.7% | -$17.2M-3.2% | -$19.8M-17.7% | -$18.3M-1045.3% | -$18.3M-12.9% | -$16.7M-37.9% | -$16.8M-7.5% |
| Depreciation & Amortization | $24K-25.0% | $34K-8.1% | $33K-15.4% | $32K-91.4% | $32K-91.4% | $37K-89.8% | $39K-89.1% | $371K+3.6% |
| Stock-Based Compensation | $1.5M-7.5% | $1.4M-7.7% | N/A | $1.4M-37.8% | $1.7M-39.7% | $1.5M-42.2% | N/A | $2.2M-33.1% |
| Capital Expenditures | $0-100.0% | $0-100.0% | $15K-73.2% | -$1K0.0% | $11K+175.0% | $4K-99.3% | $56K-71.6% | $1K-97.7% |
| Free Cash Flow | -$14.6M+20.4% | -$19.7M-7.7% | -$17.2M-2.9% | -$19.8M-17.7% | -$18.3M-1043.1% | -$18.3M-8.9% | -$16.7M-36.1% | -$16.8M-7.2% |
| Investing Cash Flow | -$12.2M-211.3% | $20.8M-27.5% | $18.4M+138.2% | $12.0M-29.7% | $11.0M+372.9% | $28.7M+9.7% | $7.7M+399.2% | $17.1M+150.9% |
| Financing Cash Flow | $143K+38.8% | $0-100.0% | $392K+127.9% | $0 | $103K-27.0% | $10K | $172K-40.3% | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PMVP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -25.3%-10.2pp | -20.5%-9.6pp | N/A | -17.4%-7.7pp | -15.1%-14.5pp | -10.9%-3.7pp | N/A | -9.7%-2.7pp |
| Return on Assets | -22.0%-8.2pp | -18.7%-8.5pp | N/A | -15.7%-7.1pp | -13.9%-13.4pp | -10.2%-3.8pp | N/A | -8.6%-2.2pp |
| Current Ratio | 7.70-4.8x | 11.14-5.6x | 10.09-2.1x | 10.76-3.2x | 12.52-6.7x | 16.750.0x | 12.22-2.6x | 13.98-5.2x |
| Debt-to-Equity | 0.15+0.1x | 0.100.0x | 0.110.0x | 0.110.0x | 0.090.0x | 0.070.0x | 0.090.0x | 0.130.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc PMVP | FY2025 | N/A | -$77.7M | N/A | $95.7M | — |
| Prelude Therapeutics Incorporated PRLD | FY2025 | $12.1M | -$99.5M | N/A | $292.9M | 70/100 |
| Adlai Nortye Group Ltd. ANL | FY2025 | $5.0M | -$109.2M | N/A | $971.8M | 32/100 |
| MiNK Therapeutics, Inc. INKT | FY2025 | N/A | -$12.5M | N/A | $63.5M | — |
| Applied Therapeutics, Inc. APLT | FY2024 | $455K | -$105.6M | N/A | $14.9M | — |
| Celularity Inc. CELU | FY2025 | $26.6M | -$91.7M | N/A | $51.9M | 50/100 |
Where PMV Pharmaceuticals, Inc Ranks
Frequently Asked Questions
Is PMV Pharmaceuticals, Inc profitable?
No, PMV Pharmaceuticals, Inc (PMVP) reported a net income of -$77.7M in fiscal year 2025.
What is PMV Pharmaceuticals, Inc's EBITDA?
PMV Pharmaceuticals, Inc (PMVP) had EBITDA of -$86.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is PMV Pharmaceuticals, Inc's return on equity (ROE)?
PMV Pharmaceuticals, Inc (PMVP) has a return on equity of -74.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is PMV Pharmaceuticals, Inc's free cash flow?
PMV Pharmaceuticals, Inc (PMVP) recorded an outflow of $73.6M in free cash flow during fiscal year 2025. This represents a -41.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is PMV Pharmaceuticals, Inc's operating cash flow?
PMV Pharmaceuticals, Inc (PMVP) recorded an outflow of $73.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are PMV Pharmaceuticals, Inc's total assets?
PMV Pharmaceuticals, Inc (PMVP) had $116.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are PMV Pharmaceuticals, Inc's capital expenditures?
PMV Pharmaceuticals, Inc (PMVP) invested $29K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does PMV Pharmaceuticals, Inc spend on research and development?
PMV Pharmaceuticals, Inc (PMVP) invested $69.9M in research and development during fiscal year 2025.
What is PMV Pharmaceuticals, Inc's current ratio?
PMV Pharmaceuticals, Inc (PMVP) had a current ratio of 10.09 as of fiscal year 2025, which is generally considered healthy.
What is PMV Pharmaceuticals, Inc's debt-to-equity ratio?
PMV Pharmaceuticals, Inc (PMVP) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is PMV Pharmaceuticals, Inc's return on assets (ROA)?
PMV Pharmaceuticals, Inc (PMVP) had a return on assets of -66.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is PMV Pharmaceuticals, Inc's P/E ratio?
PMV Pharmaceuticals, Inc (PMVP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $95.7M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is PMV Pharmaceuticals, Inc's price-to-sales ratio?
PMV Pharmaceuticals, Inc (PMVP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $95.7M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does PMV Pharmaceuticals, Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, PMV Pharmaceuticals, Inc (PMVP) held $112.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $73.6M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is PMV Pharmaceuticals, Inc's Piotroski F-Score?
PMV Pharmaceuticals, Inc (PMVP) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are PMV Pharmaceuticals, Inc's earnings high quality?
PMV Pharmaceuticals, Inc (PMVP) reported a net loss of $77.7M while operations used $73.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can PMV Pharmaceuticals, Inc cover its interest payments?
PMV Pharmaceuticals, Inc (PMVP) reported an operating loss of $86.2M against $6.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.